Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Education, Pharmacy | 6 | 2024 | 150 | 1.430 |
Why?
|
| School Admission Criteria | 3 | 2018 | 35 | 1.290 |
Why?
|
| Pharmaceutical Services | 2 | 2020 | 52 | 1.230 |
Why?
|
| Students, Pharmacy | 5 | 2024 | 123 | 1.060 |
Why?
|
| Medication Adherence | 5 | 2018 | 133 | 0.890 |
Why?
|
| College Admission Test | 3 | 2018 | 13 | 0.880 |
Why?
|
| Schools, Pharmacy | 3 | 2020 | 55 | 0.860 |
Why?
|
| Pharmacy | 3 | 2020 | 55 | 0.810 |
Why?
|
| Curriculum | 4 | 2024 | 398 | 0.710 |
Why?
|
| Health Occupations | 1 | 2018 | 19 | 0.590 |
Why?
|
| Antiviral Agents | 2 | 2016 | 178 | 0.580 |
Why?
|
| Ganciclovir | 1 | 2016 | 24 | 0.530 |
Why?
|
| Educational Measurement | 1 | 2018 | 196 | 0.530 |
Why?
|
| Cytomegalovirus | 1 | 2016 | 29 | 0.530 |
Why?
|
| Cytomegalovirus Infections | 1 | 2016 | 34 | 0.520 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 61 | 0.510 |
Why?
|
| Education, Pharmacy, Graduate | 1 | 2016 | 19 | 0.500 |
Why?
|
| Kidney Transplantation | 1 | 2016 | 192 | 0.450 |
Why?
|
| Health Literacy | 1 | 2016 | 132 | 0.440 |
Why?
|
| Graft Rejection | 3 | 2018 | 177 | 0.380 |
Why?
|
| Mycoses | 1 | 2009 | 152 | 0.300 |
Why?
|
| Universities | 2 | 2018 | 175 | 0.280 |
Why?
|
| Health Personnel | 3 | 2016 | 256 | 0.270 |
Why?
|
| Antifungal Agents | 1 | 2009 | 347 | 0.270 |
Why?
|
| Organ Transplantation | 2 | 2018 | 48 | 0.270 |
Why?
|
| Pharmacists | 2 | 2020 | 144 | 0.270 |
Why?
|
| Humans | 17 | 2024 | 52483 | 0.220 |
Why?
|
| Computers, Handheld | 2 | 2013 | 25 | 0.210 |
Why?
|
| Anxiety | 1 | 2024 | 300 | 0.190 |
Why?
|
| Retrospective Studies | 3 | 2018 | 6607 | 0.170 |
Why?
|
| Young Adult | 3 | 2024 | 4329 | 0.170 |
Why?
|
| Problem-Based Learning | 1 | 2020 | 51 | 0.160 |
Why?
|
| Adult | 5 | 2024 | 14161 | 0.160 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 243 | 0.160 |
Why?
|
| Depression | 1 | 2023 | 600 | 0.150 |
Why?
|
| Middle Aged | 4 | 2018 | 13028 | 0.150 |
Why?
|
| Leadership | 1 | 2018 | 103 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 178 | 0.130 |
Why?
|
| Serologic Tests | 1 | 2016 | 25 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 188 | 0.130 |
Why?
|
| Opportunistic Infections | 1 | 2016 | 56 | 0.130 |
Why?
|
| Reminder Systems | 1 | 2016 | 28 | 0.130 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 25 | 0.130 |
Why?
|
| Professional Role | 1 | 2016 | 78 | 0.120 |
Why?
|
| Male | 5 | 2024 | 26761 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 321 | 0.120 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 86 | 0.120 |
Why?
|
| Female | 4 | 2024 | 28171 | 0.110 |
Why?
|
| Seizures | 1 | 2016 | 208 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 488 | 0.100 |
Why?
|
| Incidence | 1 | 2016 | 1062 | 0.100 |
Why?
|
| Logistic Models | 1 | 2016 | 925 | 0.100 |
Why?
|
| Longitudinal Studies | 2 | 2024 | 747 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 2279 | 0.090 |
Why?
|
| Prevalence | 2 | 2024 | 1006 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2009 | 206 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2009 | 110 | 0.080 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 1678 | 0.080 |
Why?
|
| Antihypertensive Agents | 1 | 2009 | 132 | 0.070 |
Why?
|
| Critical Illness | 1 | 2009 | 317 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2016 | 5422 | 0.060 |
Why?
|
| Hypertension | 1 | 2009 | 565 | 0.060 |
Why?
|
| Self Report | 1 | 2024 | 210 | 0.050 |
Why?
|
| Videoconferencing | 1 | 2020 | 38 | 0.040 |
Why?
|
| Education, Distance | 1 | 2020 | 42 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2020 | 230 | 0.040 |
Why?
|
| Social Responsibility | 1 | 2018 | 25 | 0.040 |
Why?
|
| Goals | 1 | 2018 | 43 | 0.040 |
Why?
|
| Communication | 1 | 2020 | 257 | 0.040 |
Why?
|
| Consensus | 1 | 2018 | 181 | 0.030 |
Why?
|
| Graft Survival | 1 | 2016 | 160 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 585 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 2099 | 0.030 |
Why?
|
| Atenolol | 1 | 2009 | 13 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 2009 | 48 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 3889 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 467 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 490 | 0.010 |
Why?
|